http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer
Asami Ikeda,Ken Yamaguchi,Hajime Yamakage,Kaoru Abiko,Noriko Satoh-Asahara,Kenji Takakura,Ikuo Konishi 대한산부인과학회 2020 Obstetrics & Gynecology Science Vol.63 No.6
ObjectiveThe need for tailoring ovarian cancer treatments to individual patients is increasing. This study aimed to evaluate theprognostic value of pretreatment laboratory test data for predicting the response and survival outcomes of platinumbasedchemotherapy in ovarian cancer. MethodsWe enrolled 270 patients with ovarian cancer diagnosed at the Kyoto Medical Center (n=120; group A) and KyotoUniversity (n=150; group B). Data on 9 blood parameters (neutrophil to lymphocyte ratio [NLR], platelet to lymphocyterate [PLR], C-reactive protein, lactate dehydrogenase [LDH], glucose, total cholesterol, high-density lipoprotein [HDL],low-density lipoprotein, and triglyceride levels), cancer pathology, cancer stage, cytoreduction outcomes, serumcancer antigen 125 levels, platinum-free interval (PFI), disease-free survival (DFS), and overall survival were assessedretrospectively. ResultsNLR, PLR, LDH, and HDL were significantly different in advanced stage patients (P<0.001, <0.001, 0.029, and <0.001,respectively). The Kaplan-Meier curves revealed that high LDH level (≥250 U/L) was associated with reduced PFI(P=0.037 and 0.012) and DFS (P=0.007 and 0.002) in groups A and B, respectively. High NLR (≥4) was associated withreduced DFS in both groups (P=0.036 and 0.005, respectively). LDH showed higher area under the curve (AUC) valuesin predicting platinum resistance with a PFI of less than 6 months and 12 months (AUC=0.606 and 0.646, respectively)than NLR. In the multivariate analysis, LDH remained significant (P=0.019) after adjusting for the 9 blood parameters. ConclusionSerum LDH level may possibly predict platinum resistance and prognosis in ovarian cancer and may be useful whendeveloping precision medicine for individual patients.
( Norihiro Imai ),( Kenji Ikeda ),( Yuya Seko ),( Yusuke Kawamura ),( Hitomi Sezaki ),( Tetsuya Hosaka ),( Norio Akuta ),( Masahiro Kobayashi ),( Satoshi Saitoh ),( Fumitaka Suzuki ),( Yoshiyuki Suzuk 대한간학회 2013 Gut and Liver Vol.7 No.2
Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure, little prospective data are available regarding the clinical toxicity of chemotherapeutic agents used to treat HCC patients with chronic renal failure. In a phase II study, the plasma concentration of total platinum in patients who received miriplatin was very low, and no severe renal toxicity caused by miriplatin injection was reported. Here, we present three cases of HCC with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin. All cases were male, ages 72, 84, and 83 years, and had serum creatinine levels of 2.3, 1.6, and 1.9 mg/dL, respectively. Their estimated glomerular filtration rates were 21.9, 20.3, and 22.2 mL/min, respectively. All cases were treated for unresectable HCC with transcatheter arterial chemotherapy with miriplatin. No serious adverse events were observed, and serum creatinine levels did not elevate, even in the patient who experienced renal failure caused by cisplatin administration. These results might suggest that transcatheter arterial chemotherapy with miriplatin can be safely used in HCC patients with chronic renal failure. (Gut Liver 2013;7:246-251)